FI7750U1 - Doseringsform innehållande oxikodon och naloxon - Google Patents

Doseringsform innehållande oxikodon och naloxon

Info

Publication number
FI7750U1
FI7750U1 FI20070153U FIU20070153U FI7750U1 FI 7750 U1 FI7750 U1 FI 7750U1 FI 20070153 U FI20070153 U FI 20070153U FI U20070153 U FIU20070153 U FI U20070153U FI 7750 U1 FI7750 U1 FI 7750U1
Authority
FI
Finland
Prior art keywords
naloxone
dosage form
sub
form containing
containing oxycodone
Prior art date
Application number
FI20070153U
Other languages
English (en)
Finnish (fi)
Inventor
Petra Leyendecker
Kevin Smith
Michael Hopp
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI7750(U1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of FIU20070153U0 publication Critical patent/FIU20070153U0/sv
Application granted granted Critical
Publication of FI7750U1 publication Critical patent/FI7750U1/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FI20070153U 2005-02-28 2007-04-13 Doseringsform innehållande oxikodon och naloxon FI7750U1 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05004377A EP1695700A1 (en) 2005-02-28 2005-02-28 Dosage form containing oxycodone and naloxone
PCT/EP2006/060341 WO2006089973A2 (en) 2005-02-28 2006-02-28 Dosage form containing oxycodone and naloxone

Publications (2)

Publication Number Publication Date
FIU20070153U0 FIU20070153U0 (sv) 2007-04-13
FI7750U1 true FI7750U1 (sv) 2008-01-22

Family

ID=34933990

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20070153U FI7750U1 (sv) 2005-02-28 2007-04-13 Doseringsform innehållande oxikodon och naloxon

Country Status (27)

Country Link
US (5) US20080145429A1 (sv)
EP (5) EP1695700A1 (sv)
JP (2) JP2008531650A (sv)
KR (1) KR20070107805A (sv)
CN (2) CN101128191A (sv)
AT (1) ATE517611T1 (sv)
AU (2) AU2006217870B2 (sv)
BR (1) BRPI0607975A2 (sv)
CA (3) CA2768075A1 (sv)
CY (1) CY1111967T1 (sv)
DE (2) DE19167974T1 (sv)
DK (2) DK1855657T3 (sv)
ES (1) ES2370409T3 (sv)
FI (1) FI7750U1 (sv)
HK (1) HK1111604A1 (sv)
HR (1) HRP20110775T1 (sv)
IL (2) IL185514A0 (sv)
ME (1) ME01262B (sv)
MX (1) MX2007010494A (sv)
NZ (1) NZ588875A (sv)
PL (1) PL1855657T3 (sv)
PT (1) PT1855657E (sv)
RS (1) RS51984B (sv)
RU (1) RU2428985C2 (sv)
SI (1) SI1855657T1 (sv)
UA (1) UA93543C2 (sv)
WO (1) WO2006089973A2 (sv)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50070B (sr) 1997-12-22 2009-01-22 Euro-Celtique S.A., Oralni dozni oblik sa kombinacijom opijatnog agonista i antagonista
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
ATE493130T1 (de) 2001-05-11 2011-01-15 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
DK2939696T3 (en) 2001-10-18 2016-05-23 Nektar Therapeutics Polymer Conjugates of Opioid Antagonists
EP1492505B1 (en) * 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
BRPI0606339A2 (pt) * 2005-01-28 2009-06-16 Euro Celtique Sa formas farmacêuticas resistentes a álcool
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
DE202006018609U1 (de) * 2006-08-29 2007-05-16 Euro-Celtique S.A. Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung
MX2009004965A (es) * 2006-11-07 2009-06-05 Nektar Therapeutics Al Corp Formas de dosificacion y co-administracion de un agonista de opioides y un antagonista de opioides.
US20090004231A1 (en) 2007-06-30 2009-01-01 Popp Shane M Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring
EP2042176A1 (en) * 2007-09-26 2009-04-01 Euro-Celtique S.A. Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease
JP5651818B2 (ja) 2007-12-17 2015-01-14 パラディン ラブス インコーポレーテッド 誤用を防止するための放出制御製剤
NZ586792A (en) 2008-01-25 2012-09-28 Gruenenthal Chemie Tamper resistant controlled release pharmaceutical tablets form having convex and concave surfaces
BRPI0912014A2 (pt) 2008-05-09 2019-03-06 Grünenthal GmbH processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob uso de uma etapa de congelamento por atomização
KR20130105935A (ko) * 2008-07-07 2013-09-26 유로-셀티큐 에스.에이. 요폐의 치료를 위한 아편유사제 길항제의 용도
CA2746888C (en) 2008-12-16 2015-05-12 Labopharm (Barbados) Limited Misuse preventative, controlled release formulation
LT2405915T (lt) * 2009-03-10 2019-03-12 Euro-Celtique S.A. Greito atpalaidavimo farmacinė kompozicija, apimanti oksikodoną ir naloksoną
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
ES2718688T3 (es) 2009-07-22 2019-07-03 Gruenenthal Gmbh Forma de dosificación resistente a la manipulación para opioides sensibles a la oxidación
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
ES2606227T3 (es) 2010-02-03 2017-03-23 Grünenthal GmbH Preparación de una composición farmacéutica en polvo mediante una extrusora
SG184523A1 (en) 2010-05-10 2012-11-29 Euro Celtique Sa Pharmaceutical compositions comprising hydromorphone and naloxone
CA2798884C (en) 2010-05-10 2016-09-13 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
WO2011141490A1 (en) 2010-05-10 2011-11-17 Euro-Celtique S.A. Combination of active loaded granules with additional actives
MX355644B (es) * 2010-08-13 2018-04-26 Euro Celtique S A Star Uso de aglutinantes para fabricar formulaciones estables al almacenamiento.
NZ608865A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising an anionic polymer
PE20131102A1 (es) 2010-09-02 2013-10-12 Gruenenthal Chemie Forma de dosificacion resistente a manipulacion que comprende una sal inorganica
CN103347495B (zh) * 2010-12-28 2017-06-20 欧洲凯尔特公司 治疗帕金森病的阿片样激动剂与阿片样拮抗剂的组合
SI2736497T1 (sl) 2011-07-29 2017-12-29 Gruenenthal Gmbh Tableta, odporna proti zlorabi, ki zagotavlja takojšnje sproščanje zdravila
EP2736495B1 (en) 2011-07-29 2017-08-23 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
CA3120681C (en) 2012-04-17 2024-05-28 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
JP6282261B2 (ja) 2012-04-18 2018-02-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 不正使用防止および過量放出防止医薬剤形
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AR096439A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido que contiene una o más partículas
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
AU2014295042B2 (en) 2013-07-23 2017-03-30 Mundipharma Pty Limited A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
JP6232135B2 (ja) 2013-11-13 2017-11-15 ユーロ−セルティーク エス．エイ． 疼痛およびオピオイドによる腸機能障害症候群の治療のためのヒドロモルホンおよびナロキソン
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
MX365383B (es) 2014-03-14 2019-05-31 Opiant Pharmaceuticals Inc Medicamentos de administracion nasal y metodos para su uso.
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
JP2017516789A (ja) 2014-05-26 2017-06-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エタノール過量放出に対して防護されている多粒子
WO2016016431A1 (en) * 2014-08-01 2016-02-04 Krka, D.D., Novo Mesto Pharmaceutical formulation comprising an opioid agonist and an opioid antagonist prepared by melt granulation using lipid esters
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
US20160256453A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation induced by high opiate dosage regimen
US20160256451A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Dosage of naloxone
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
WO2016193456A2 (en) * 2015-06-03 2016-12-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US20210043293A1 (en) * 2019-08-05 2021-02-11 RxAssurance Corporation (d/b/a OpiSafe) Techniques for providing interactive clinical decision support for drug dosage reduction
US20240131022A1 (en) * 2022-03-11 2024-04-25 John Abernethy Opioid overdose reversal mixtures

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (sv) * 1960-11-29
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
NL6714885A (sv) * 1967-11-02 1969-05-06
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3773955A (en) 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
FR2183546B1 (sv) * 1972-05-10 1975-06-20 Servier Lab
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) * 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
US3966940A (en) 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US3966040A (en) * 1975-03-05 1976-06-29 Hazelwood John E Combined vibratory feeder drive unit, vibratory feeder bowl, and parts separator
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
EP0352361A1 (en) 1988-07-29 1990-01-31 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
IL109460A (en) * 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
DE4325465B4 (de) * 1993-07-29 2004-03-04 Zenz, Michael, Prof. Dr.med. Orales pharmazeutisches Präparat für die Schmerztherapie
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5865161A (en) * 1995-01-04 1999-02-02 Bruce; Norman R. Baseball pitching device
US20020006964A1 (en) * 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US6207142B1 (en) * 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
DK1009387T3 (da) * 1997-07-02 2006-08-14 Euro Celtique Sa Stabiliserede tramadolformuleringer med langvarig frigivelse
US6228863B1 (en) * 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
RS50070B (sr) * 1997-12-22 2009-01-22 Euro-Celtique S.A., Oralni dozni oblik sa kombinacijom opijatnog agonista i antagonista
CN1303286A (zh) * 1998-03-27 2001-07-11 法玛西雅厄普约翰美国公司 卡麦角林在治疗多动腿综合征中的应用
US20030178031A1 (en) * 1999-05-07 2003-09-25 Du Pen, Inc. Method for cancer pain treatment
CA2376277C (en) * 1999-06-11 2011-03-15 Telstra New Wave Pty Ltd A method of developing an interactive system
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
US6258042B1 (en) * 1999-09-17 2001-07-10 James S. Factor Visual analog scale and method of use for the diagnosis and/or treatment of physical pain
JP2003522146A (ja) * 2000-02-08 2003-07-22 ユーロ−セルティーク，エス．エイ． 外圧に抵抗性の経口オピオイドアゴニスト製剤
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
EA006396B1 (ru) * 2001-04-19 2005-12-29 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл Эл Си Конденсированные бициклические аминокислоты
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
AU2002303718B2 (en) * 2001-05-11 2008-02-28 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
ATE493130T1 (de) * 2001-05-11 2011-01-15 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
DK1416842T3 (da) * 2001-07-18 2009-03-16 Euro Celtique Sa Farmaceutiske kombinationer af oxycodon og naloxon
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
MXPA04002709A (es) * 2001-09-24 2005-06-06 Johnson & Johnson Derivados articonvulsivos utiles para el tratamiento del sindrome de extremidades inquietas y trastorno periodico del movimiento de extremidades.
WO2003073937A1 (en) 2002-03-06 2003-09-12 Euro-Celtique S.A. Analog scale for measuring pain
EP1492505B1 (en) * 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
JP4694207B2 (ja) * 2002-07-05 2011-06-08 コルジウム ファーマシューティカル， インコーポレイテッド オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US7700626B2 (en) * 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone

Also Published As

Publication number Publication date
CN104027297A (zh) 2014-09-10
HRP20110775T1 (hr) 2011-11-30
RU2007135991A (ru) 2009-04-10
IL185514A0 (en) 2008-01-06
IL196539A0 (en) 2011-07-31
US20140031382A1 (en) 2014-01-30
PL1855657T3 (pl) 2012-03-30
CY1111967T1 (el) 2015-11-04
AU2009201019A1 (en) 2009-04-02
ME01262B (me) 2013-06-20
NZ588875A (en) 2012-02-24
US20080145429A1 (en) 2008-06-19
UA93543C2 (ru) 2011-02-25
SI1855657T1 (sl) 2011-11-30
EP1855657A2 (en) 2007-11-21
EP2258353A2 (en) 2010-12-08
EP3578173A1 (en) 2019-12-11
DK200700248U1 (da) 2007-12-14
EP3578173B1 (en) 2022-10-26
DE202006020095U1 (de) 2007-11-08
CA2599156A1 (en) 2006-08-31
EP1695700A1 (en) 2006-08-30
RU2428985C2 (ru) 2011-09-20
US20180008593A1 (en) 2018-01-11
AU2009201019B2 (en) 2011-05-26
WO2006089973A3 (en) 2006-12-28
FIU20070153U0 (sv) 2007-04-13
EP1855657B1 (en) 2011-07-27
DE19167974T1 (de) 2021-12-30
EP2258353A3 (en) 2012-05-09
KR20070107805A (ko) 2007-11-07
ES2370409T3 (es) 2011-12-15
EP2962686B1 (en) 2019-04-10
PT1855657E (pt) 2011-10-31
WO2006089973A2 (en) 2006-08-31
ATE517611T1 (de) 2011-08-15
AU2006217870A1 (en) 2006-08-31
RS51984B (en) 2012-02-29
DK200700248U3 (da) 2008-02-08
BRPI0607975A2 (pt) 2009-10-27
DK1855657T3 (da) 2011-10-17
US20110172259A1 (en) 2011-07-14
JP2008531650A (ja) 2008-08-14
MX2007010494A (es) 2008-01-16
CN101128191A (zh) 2008-02-20
JP6235962B2 (ja) 2017-11-22
EP2962686A1 (en) 2016-01-06
US20120225901A1 (en) 2012-09-06
CA2768075A1 (en) 2006-08-31
CA2599156C (en) 2012-05-01
JP2014169303A (ja) 2014-09-18
HK1111604A1 (en) 2008-08-15
AU2006217870B2 (en) 2008-12-18
CA2960011A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
FI7750U1 (sv) Doseringsform innehållande oxikodon och naloxon
EA200900260A1 (ru) Гранулы и орально дезинтегрируемые таблетки, содержащие оксикодон
WO2009156462A3 (en) Organic compounds
WO2009152356A3 (en) Compounds and compositions useful for the treatment of malaria
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
WO2007115821A3 (en) Organic compounds
WO2007115305A3 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
EA200970291A1 (ru) Фармацевтическая композиция, содержащая розувастатин кальция
WO2006086562A3 (en) Phenylazetidinone derivatives
EA201300465A1 (ru) Устойчивые оральные фармацевтические дозированные формы, содержащие опиоидный анальгетик
EA200602129A1 (ru) Новое применение пептидных соединений для лечения дискинезии
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
WO2007133865A3 (en) Hcv/hiv inhibitors an their uses
EA201270590A1 (ru) Ингибиторы акт
EA201170680A1 (ru) Ингибиторы акт и p70 s6-киназы
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
WO2006047415A3 (en) FACTOR Xa COMPOUNDS
WO2008054808A3 (en) Elvucitabine pharmaceutical compositions
WO2006031929A3 (en) Thiazolopyridine kinase inhibitors
WO2008098143A3 (en) Antimicrobial compounds and methods of use
WO2007115287A3 (en) Combination of organic compounds
WO2006055663A3 (en) The use of novel antibacterial compounds
EA201070923A1 (ru) Комбинация бис-тиазолиевой соли или одного из её предшественников и артемизинина и одного из его производных для лечения тяжелой формы малярии
WO2007092741A3 (en) Hydroxylamines and derivatives as anti-angiogenic agents

Legal Events

Date Code Title Description
FGU Utility model registered

Ref document number: 7750

Country of ref document: FI

MAU Utility model expired